- In recent weeks, Michael Burry increased his position in Zoetis, reflecting his preference for consumer and healthcare names over the AI-focused semiconductor sector.
- This portfolio shift draws fresh attention to Zoetis’ role as a pure-play animal health company, potentially highlighting its differentiated exposure versus high-profile technology trades.
- We’ll now explore how Burry’s increased stake interacts with Zoetis’ existing animal health growth thesis and affects its broader investment narrative.
AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Zoetis Investment Narrative Recap
To own Zoetis, you need to believe in the long term need for animal health treatments across pets and livestock, supported by consistent innovation in pain, parasiticide and dermatology therapies. Michael Burry’s larger position may spotlight this thesis, but it does not directly change the near term focus on scaling the osteoarthritis (OA) pain portfolio or the key risk from intensifying competition around Simparica Trio and dermatology products.
The most relevant recent development is the launch of Lenivia in Canada and the EU, expanding Zoetis’ OA pain offering for dogs with a long acting monoclonal antibody. This directly ties into the OA growth story that has faced adoption headwinds with Librela, and it gives Zoetis another shot at reinforcing its innovation credentials while addressing concerns about how fully the OA franchise can contribute to future earnings.
Yet against this backdrop, investors should be aware that rising competition and safety concerns could still pressure Zoetis’ margins and long term OA adoption...
Read the full narrative on Zoetis (it's free!)
Zoetis’ narrative projects $10.7 billion revenue and $3.1 billion earnings by 2029. This requires 3.9% yearly revenue growth and a roughly $0.4 billion earnings increase from $2.7 billion today.
Uncover how Zoetis' forecasts yield a $114.76 fair value, a 48% upside to its current price.
Exploring Other Perspectives
Some of the lowest analysts were already assuming only about US$10.4 billion in 2029 revenue and US$3.0 billion in earnings, so if you see Burry’s move as encouraging, remember these more cautious forecasts highlight how much opinions can differ and why it is worth comparing several views before deciding what Zoetis is really worth.
Explore 10 other fair value estimates on Zoetis - why the stock might be worth just $90.00!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Zoetis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.
Searching For A Fresh Perspective?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com